Literature DB >> 30297816

Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Novel Potential Biomarker in Gastroenteropancreatic Neuroendocrine Tumors.

Aura D Herrera-Martínez1,2, Manuel D Gahete1,3,4,5, Rafael Sánchez-Sánchez1,6, Emilia Alors-Perez1,3,4,5, Sergio Pedraza-Arevalo1,3,4,5, Raquel Serrano-Blanch1,7, Antonio J Martínez-Fuentes1,3,4,5, Maria A Gálvez-Moreno8,9, Justo P Castaño10,11,12,13, Raúl M Luque14,15,16,17.   

Abstract

OBJECTIVES: The association between the presence and alterations of the components of the ghrelin system and the development and progression of neuroendocrine tumors (NETs) is still controversial and remains unclear.
METHODS: Here, we systematically evaluated the expression levels (by quantitative-PCR) of key ghrelin system components of in gastroenteropancreatic (GEP)-NETs, as compared to non-tumor adjacent (NTA; n = 42) and normal tissues (NT; n = 14). Then, we analyzed their putative associations with clinical-histological characteristics.
RESULTS: The results indicate that ghrelin and its receptor GHSR1a are present in a high proportion of normal tissues, while the enzyme ghrelin-O-acyltransferase (GOAT) and the splicing variants In1-ghrelin and GHSR1b were present in a lower proportion of normal tissues. In contrast, all ghrelin system components were present in a high proportion of tumor and NTA tissues. GOAT was significantly overexpressed (by quantitative-PCR (qPCR)) in tumor samples compared to NTA, while a trend was found for ghrelin, In1-ghrelin and GHSR1a. In addition, expression of these components displayed significant correlations with key clinical parameters. The marked overexpression of GOAT in tumor samples compared to NTA regions was confirmed by IHC, revealing that this enzyme is particularly overexpressed in gastrointestinal NETs, where it is directly correlated with tumor diameter.
CONCLUSIONS: These results provide novel information on the presence and potential pathophysiological implications of the ghrelin system components in GEP-NETs, wherein GOAT might represent a novel diagnostic biomarker.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30297816      PMCID: PMC6175927          DOI: 10.1038/s41424-018-0058-8

Source DB:  PubMed          Journal:  Clin Transl Gastroenterol        ISSN: 2155-384X            Impact factor:   4.488


  57 in total

1.  Ghrelin inhibits proliferation and increases T-type Ca2+ channel expression in PC-3 human prostate carcinoma cells.

Authors:  Nundehui Díaz-Lezama; Mariana Hernández-Elvira; Alejandro Sandoval; Alma Monroy; Ricardo Felix; Eduardo Monjaraz
Journal:  Biochem Biophys Res Commun       Date:  2010-10-30       Impact factor: 3.575

2.  Ghrelin promotes renal cell carcinoma metastasis via Snail activation and is associated with poor prognosis.

Authors:  Tsung-Chieh Lin; Yu-Peng Liu; Yung-Chieh Chan; Chia-Yi Su; Yuan-Feng Lin; Shih-Lan Hsu; Chung-Shi Yang; Michael Hsiao
Journal:  J Pathol       Date:  2015-05-28       Impact factor: 7.996

3.  The expression of ghrelin O-acyltransferase (GOAT) in human tissues.

Authors:  Chung Thong Lim; Blerina Kola; Ashley Grossman; Márta Korbonits
Journal:  Endocr J       Date:  2011-06-04       Impact factor: 2.349

4.  Evidence that endogenous SST inhibits ACTH and ghrelin expression by independent pathways.

Authors:  Raul M Luque; Manuel D Gahete; Ute Hochgeschwender; Rhonda D Kineman
Journal:  Am J Physiol Endocrinol Metab       Date:  2006-08       Impact factor: 4.310

Review 5.  Gastrointestinal neuroendocrine tumors (NETs): new diagnostic and therapeutic challenges.

Authors:  J P Castaño; A Sundin; H R Maecke; C Villabona; R Vazquez-Albertino; E Navarro; K Oberg
Journal:  Cancer Metastasis Rev       Date:  2014-03       Impact factor: 9.264

Review 6.  Translational research in neuroendocrine tumors: pitfalls and opportunities.

Authors:  J Capdevila; O Casanovas; R Salazar; D Castellano; A Segura; P Fuster; J Aller; R García-Carbonero; P Jimenez-Fonseca; E Grande; J P Castaño
Journal:  Oncogene       Date:  2016-09-19       Impact factor: 9.867

7.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach.

Authors:  M Kojima; H Hosoda; Y Date; M Nakazato; H Matsuo; K Kangawa
Journal:  Nature       Date:  1999-12-09       Impact factor: 49.962

Review 8.  Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).

Authors:  R Garcia-Carbonero; J Capdevila; G Crespo-Herrero; J A Díaz-Pérez; M P Martínez Del Prado; V Alonso Orduña; I Sevilla-García; C Villabona-Artero; A Beguiristain-Gómez; M Llanos-Muñoz; M Marazuela; C Alvarez-Escola; D Castellano; E Vilar; P Jiménez-Fonseca; A Teulé; J Sastre-Valera; M Benavent-Viñuelas; A Monleon; R Salazar
Journal:  Ann Oncol       Date:  2010-02-05       Impact factor: 32.976

9.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

10.  In1-ghrelin splicing variant is overexpressed in pituitary adenomas and increases their aggressive features.

Authors:  Alejandro Ibáñez-Costa; Manuel D Gahete; Esther Rivero-Cortés; David Rincón-Fernández; Richard Nelson; Manuel Beltrán; Andrés de la Riva; Miguel A Japón; Eva Venegas-Moreno; Ma Ángeles Gálvez; Juan A García-Arnés; Alfonso Soto-Moreno; Jennifer Morgan; Natia Tsomaia; Michael D Culler; Carlos Dieguez; Justo P Castaño; Raúl M Luque
Journal:  Sci Rep       Date:  2015-03-04       Impact factor: 4.379

View more
  4 in total

Review 1.  Ghrelin and Cancer: Examining the Roles of the Ghrelin Axis in Tumor Growth and Progression.

Authors:  Anuhya S Kotta; Abigail S Kelling; Karen A Corleto; Yuxiang Sun; Erin D Giles
Journal:  Biomolecules       Date:  2022-03-22

Review 2.  Role of the Ghrelin System in Colorectal Cancer.

Authors:  Aldona Kasprzak
Journal:  Int J Mol Sci       Date:  2022-05-11       Impact factor: 6.208

3.  Sarcopenia and Ghrelin System in the Clinical Outcome and Prognosis of Gastroenteropancreatic Neuroendocrine Neoplasms.

Authors:  Yiraldine Herrera-Martínez; Carlos Alzas Teomiro; Soraya León Idougourram; María José Molina Puertas; Alfonso Calañas Continente; Raquel Serrano Blanch; Justo P Castaño; María Ángeles Gálvez Moreno; Manuel D Gahete; Raúl M Luque; Aura D Herrera-Martínez
Journal:  Cancers (Basel)       Date:  2021-12-27       Impact factor: 6.639

Review 4.  Correct Identification of Cell of Origin May Explain Many Aspects of Cancer: The Role of Neuroendocrine Cells as Exemplified from the Stomach.

Authors:  Helge Waldum; Patricia G Mjønes
Journal:  Int J Mol Sci       Date:  2020-08-11       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.